Christof Vulsteke, MD, PhD, discusses results from the KEYNOTE-905 trial, evaluating perioperative EV/pembrolizumab in cisplatin-ineligible MIBC.
Christof Vulsteke, MD, PhD
Advertisement
Articles by Christof Vulsteke, MD, PhD
Advertisement
Latest Updated Articles
Christof Vulsteke, MD, PhD, breaks down findings, implications of KEYNOTE-905Published: October 31st 2025 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
Annual ACS NCDB report details national trends in prostate cancer care
2
Pearls & Perspectives: Mindfulness, Performance, and Prostate Cancer Care, with Phillip M. Pierorazio, MD
3
Docetaxel plus tumor-targeting IL-12 yields promising activity in mCRPC
4
FDA provides guidance on development pathway for testosterone therapy for women
5